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HDL-C, mg/dL
-0.9 (-6.5, 4.7) 0.7 (-2.6, 3.9) -9.1 (-14.1, -4.1) -12.4 (-19.1, -5.8) 0.002 -3.1 (-9.4, 3.2) -6.2 (-11.5, -0.8) -8.0 (-13.7, -2.3) -14.7 (-20.0, -9.3) 0.02 0.21
Triglycerides, mg/dL -9.5 (-31.2, 12.2) 28.9 (-40.7, 98.5) 11.3 (-19.6, 42.3) 34.2 (-21.2, 89.6) 0.45 8.5 (-16.8, 33 .9) -10.0 (-36.8, 16.8) -12.8 (-58.3, 32 .8) -1.8 (-25.3, 21.7) 0.70 0.12
Osteocalcin, ng/mL -1.8 (-3.6, 0.08) 2.2 (-0.8, 5.2) 0.5 (-1.9, 2.8) 0.5 (-3.1, 4.1) 0.23 -2.9 (-5.3, -0.6) 2.4 (-0.9, 5.8) 0.5 (-4.4, 5.4) 0.3 (-1.9, 2.6) 0.08 0.77 N Tx, nmol BCE/L 0.1 (-1.6, 1.9) 0.6 (-3.0, 4.3)
The data are mean (95% confidence interval The data are mean (95% confidence interval). LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; N Tx, N-telopeptide; BCE, bone collagen equivalent a Multiple Imputation via Predictive Mean Matching . To support analyses that were limited to participants completing the intervention treatment phase, we conducted sensitivity analyses using Multiple Imputation by Chained Equations (MICE) to obtain values for subjects with missing records. Models were fit using R version 2.14.1 (R Foundation for Statistical Computing, Vienna, Austria). Fifty replicative data sets were created, and analyses performed on each and then pooled. Significance levels were generated using nested model comparisons. In tissues with high 5α-reductase activity, such as the prostate, IDHT is greater than IT under basal conditions. Dutasteride administration at doses (0.5-mg daily), substantially lower than those used in this trial (2.5-mg daily), has been shown to nearly completely suppress IDHT to very low levels. [20] [21] [22] [23] As prostate volume was maintained in men treated with dutasteride and graded doses of testosterone, who presumably had very low IDHT, it follows that even in tissues with high 5α-reductase activity, such as the prostate, DHT is not essential for maintaining prostate volume in the range of testosterone concentrations achieved in this trial. It also follows from this model that administration of 5α-reductase inhibitor to men, who have low testosterone levels below the activation threshold of a particular tissue, may attenuate androgen effects in that tissue. Furthermore, at a given circulating concentration of testosterone and DHT, the activity of steroid 5α-reductase would determine the relative concentrations of testosterone and DHT in any tissue and whether testosterone or DHT may serve as the dominant androgen in that tissue. Thus, the suppression of prostate volume by dutasteride in older men with benign postatic hyperplasia suggests that DHT formation is important for amplifying testosterone's effect in this tissue at concentrations lower than those achieved in our trial. This argument is supported by the finding that in older men with benign prostatic hyperplasia, the largest reduction in prostate volume with dutasteride is observed in men with lowest serum testosterone levels. 38 However, as circulating testosterone concentrations are raised from mid-normal (as in the men receiving the 50-mg dose in our trial) to supraphysiologic, testosterone alone can maintain prostate volumes.
K1 and K4 are coefficients representing the tissue uptake of testosterone and DHT, respectively, and K3 and K5 are coefficients representing tissue clearance of testosterone and DHT, respectively.
